Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
News about Werewolf Therapeutics, Inc. (Nasdaq: HOWL) centers on its progress in developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Company announcements frequently highlight updates from its PREDATOR platform, which is used to design INDUKINE cytokine prodrugs and INDUCER T cell engager candidates that aim to stimulate adaptive and innate immunity while limiting systemic toxicity.
Investors and followers of HOWL can expect regular news on the clinical development of WTX-124 and WTX-330, Werewolf’s most advanced INDUKINE programs. Press releases describe Phase 1/1b and Phase 1b/2 trial updates in multiple advanced solid tumors, regulatory designations such as Fast Track status for WTX-124 in cutaneous melanoma after standard immunotherapy, and emerging data on tolerability, antitumor activity, and tumor-selective activation strategies.
News flow also covers the company’s expanding INDUCER T cell engager platform, including preclinical data for WTX-1011, an anti‑STEAP1 candidate for STEAP1-expressing cancers, and WTX-2022, targeting CDH6-expressing cancers. Werewolf reports on presentations at scientific and medical meetings, such as the Society for Immunotherapy of Cancer’s Annual Meeting and disease-focused summits, where it shares data on sequential dosing of IL‑12 and IL‑2 INDUKINE molecules, masking strategies to reduce cytokine release, and real-time pharmacokinetic insights.
Additional HOWL news items include quarterly financial results, business updates, conference participation, and partnering discussions around its broader INDUKINE portfolio, including WTX-712, WTX-518, and WTX-921. For readers tracking immuno-oncology developments, the Werewolf Therapeutics news page provides a consolidated view of clinical milestones, regulatory interactions, scientific presentations, and corporate strategy disclosures related to the company’s conditionally activated immune therapeutics.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the appointment of Meeta Chatterjee, Ph.D., as a new board member. Dr. Chatterjee brings over 30 years of experience in pharmaceutical R&D and business development, previously serving at Legend Biotech Corporation and Merck Research Labs. She aims to enhance the company's strategy as it advances its lead product candidates, WTX-124 and WTX-330, targeting solid tumors. This strategic addition is anticipated to strengthen the board's capabilities during a pivotal time for the company's development.
Werewolf Therapeutics (Nasdaq: HOWL) announced the presentation of promising preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place from November 10-14, 2021. This data showcases the potential of their INDUKINE™ molecules, specifically WTX-124 and WTX-330, in enhancing anti-tumor immune responses. The results will be included in IND applications expected to be filed in the first half of 2022. The abstracts will be available on the SITC website starting November 9, 2021.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) will present at the Next-Gen Cytokine Therapeutics Summit on September 22, 2021. Chief Scientific Officer, Cynthia Seidel-Dugan, Ph.D., will discuss advancements in cytokine therapeutics at 4:20 PM EDT, followed by Chief Medical Officer, Randi Isaacs, M.D., on a panel discussing the future of cytokine therapies at 4:50 PM EDT. The company focuses on innovative therapeutics that leverage its proprietary PREDATOR™ platform to enhance cancer treatment through conditionally activated INDUKINE™ molecules.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), based in Cambridge, Massachusetts, will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. CEO Daniel J. Hicklin, Ph.D. will provide a company overview available on-demand starting September 13 at 7:00 am EDT, archived for 90 days. Werewolf specializes in developing conditionally activated therapeutics to enhance the immune system's response to cancer, leveraging its innovative PREDATOR™ platform and its lead candidates, WTX-124 and WTX-330, for solid tumors.
Werewolf Therapeutics has announced a clinical trial collaboration with Merck to evaluate WTX-124, a conditionally activated Interleukin-2 molecule, alongside KEYTRUDA® in treating solid tumors.
This trial will assess the safety and efficacy of WTX-124 both alone and in combination with KEYTRUDA. Werewolf plans to submit an IND application to the FDA in 2022, aiming to start Phase 1 trials if approved. WTX-124 is designed to enhance treatment while minimizing toxicity, potentially improving options for cancer patients.
Werewolf Therapeutics (Nasdaq: HOWL) announced its financial results for Q2 2021. The company raised approximately $109.2 million through its IPO in May, boosting cash reserves to $183.2 million. R&D expenses rose to $7.3 million from $3.8 million year-over-year, while general and administrative costs increased to $3.7 million from $1.3 million. The net loss for Q2 stood at $10.9 million compared to $2.3 million the previous year. Werewolf aims to file INDs for its INDUKINE™ products, WTX-124 and WTX-330, and was recently added to the Russell 2000 Index.
Werewolf Therapeutics will be added to the Russell 2000® Index on June 28, 2021, a significant milestone reflecting its progress in developing cancer therapeutics.
The company is advancing its lead programs, WTX-124 and WTX-330, into clinical trials. The Russell 2000® Index is a key benchmark representing the small-cap segment of the U.S. equity market, used by many institutional investors for index funds.
Approximately $10.6 trillion in assets benchmark against Russell's indexes, underlining the importance of this inclusion for Werewolf Therapeutics.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) has appointed Chulani Karunatilake, Ph.D., as the new Chief Technology Officer (CTO). With over 30 years of experience in Chemistry and Manufacturing Controls (CMC), Dr. Karunatilake will oversee manufacturing operations as the company advances its lead therapeutic programs, WTX-124 and WTX-330, which are designed to treat cancer. His prior experience includes roles at Maverick Therapeutics and Nektar Therapeutics, emphasizing drug development and regulatory management. This appointment aims to enhance Werewolf's capabilities in immuno-oncology.
Werewolf Therapeutics (NASDAQ: HOWL) has successfully completed its initial public offering, raising $120 million in gross proceeds.
For Q1 2021, the company reported a net loss of $7.4 million, an increase from $3.8 million in Q1 2020. Cash and cash equivalents declined to $84.6 million compared to $92.6 million at the end of 2020.
Research and development expenses surged to $4.8 million, up from $2.8 million in the same quarter of 2020, reflecting the ongoing development of its lead cancer treatment programs.
Werewolf Therapeutics (NASDAQ: HOWL) appointed Mike Sherman, CEO of Chimerix, Inc., to its board of directors, enhancing the company's leadership during a critical growth phase. Sherman brings over 30 years of experience in biotechnology, including a successful tenure at Endocyte, where he led a $2.1 billion acquisition by Novartis. His expertise in corporate strategy and product focus will support Werewolf's advancements in its innovative cancer therapies, notably the WTX-124 and WTX-330 candidates, which are progressing towards clinical development.